British scientists start Phase II on COVID-19 vaccine
Researchers at the University Oxford and AstraZeneca have started enrolment for a Phase II/III trial to test a COVID-19 vaccine in 10,000 volunteers.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2000 entries already.
Entries by Thomas Gabrielczyk
SARS-CoV2 antibody tests: not suited for individual diagnosis?
An international research consortium provides data demonstrating that SARS-CoV-2 antibody tests are only useful for population-based analyses.
Vaccine to protect from any viral infection
Two companies have presented a novel vaccination concept that might protect risk groups from new SARS-CoV-2 variants.
Abivax bags €36m fund for COVID-19 programme
French Abivax SA has received a €36m non-dilutive funding from Bpifrance for its ABX464 Covid-19 programme.
4Teen4’s DPP3 predicts burn mortality
4TEEN4 Pharmaceuticals GmbH published data suggesting that high plasma levels of dipeptidyl peptidase 3 were indicative for upcoming multiple organ failure in burn patients.
Growing interest in alternative meat market
Manufacturers are keen to get involved in the alternative meat market. Investors and incubators are pushing forward start-ups.
Upscaling in the race to cultured meat
A first wave of cultured meat companies is pushing forward. European start-ups such as Mosa Meat and Peace of Meat are part of the game.
S-Protein: Glycosylation pattern revealed
British researchers have deciphered the glycosylation pattern of the viral spike protein of SARS-CoV-2 laying the foundation for vaccine development.
Newron terminates sarizotan development in Rett syndrome
Newron Pharmaceuticals S.p.A.s Sarizotan failed to meet efficacy endpoints in the Phase III STARS study.
Roche gets FDA okay for COVID-19 antibody test
Roche Diagnostics has received FDA Emergency use approval for its highly specific Elecsys antibody test.